Author Topic: VRX - Valeant Pharmaceuticals International Inc.  (Read 1334288 times)

Jurgis

  • Hero Member
  • *****
  • Posts: 4126
    • Porfolio
Re: VRX - Valeant Pharmaceuticals International Inc.
« Reply #6100 on: June 19, 2018, 06:03:50 AM »
Combining two generic drugs into one branded so they can jack up the price but can't even get it approved. Same old Valeant.

Unfortunately a lot of pharmas do this nowadays.  :-\
"Before you can be rich, you must be poor." - Nef Anyo
--------------------------------------------------------------------
"American History X", "Milk", "The Insider", "Dirty Money", "LBJ"


Spekulatius

  • Hero Member
  • *****
  • Posts: 1952
Re: VRX - Valeant Pharmaceuticals International Inc.
« Reply #6101 on: June 19, 2018, 10:25:47 AM »
The price dropped more than 12% today on news that one of it's pipeline drugs (a lotion to treat plaque psoriasis) was not approved by the FDA 

https://finance.yahoo.com/news/valeant-rebound-falters-key-drug-174641785.html

It says the denial isn't based on the efficacy of the drug but rather that they need to provide more data on "pharmacokinetics" (according to google, that's the movement of drugs throughout the body, which is odd considering it's a lotion, not a pill).  Seems like a bit of an overraction to a delay for a drug that is not related to efficacy or dangerous side effects. 

Someone gave a great bull thesis on this stock at one of the side events at the Fairfax AGM.  And he even suggested watching the Netflix episode to see the basis of the fraud claims.  Basically, 1) the debt is manageable now, 2) they've sold off parts of the business at non-fire sale prices and 3) the parts that are left like Bausch and Lomb and some of the skin care stuff looks like a steady profitable business that Joe Papa can turn around.

Is anyone adding to this on the big dip?

Combining two generic drugs into one branded so they can jack up the price but can't even get it approved. Same old Valeant.

Didnít realize that they are trying to market just a combo of generics. That is why pharmacokinetics are so important - the FDA wants to understand, how these drugs interact. Otherwise, Doctors could just prescribe the two generics together (which I suspect occurs already anyways). Looks like VRX R&D department didnít d their job well.
« Last Edit: June 19, 2018, 02:52:34 PM by Spekulatius »
To be a realist, one has to believe in miracles.

DeepSouth

  • Jr. Member
  • **
  • Posts: 94
Re: VRX - Valeant Pharmaceuticals International Inc.
« Reply #6102 on: June 19, 2018, 12:34:03 PM »
The price dropped more than 12% today on news that one of it's pipeline drugs (a lotion to treat plaque psoriasis) was not approved by the FDA 

https://finance.yahoo.com/news/valeant-rebound-falters-key-drug-174641785.html

It says the denial isn't based on the efficacy of the drug but rather that they need to provide more data on "pharmacokinetics" (according to google, that's the movement of drugs throughout the body, which is odd considering it's a lotion, not a pill).  Seems like a bit of an overraction to a delay for a drug that is not related to efficacy or dangerous side effects. 

Someone gave a great bull thesis on this stock at one of the side events at the Fairfax AGM.  And he even suggested watching the Netflix episode to see the basis of the fraud claims.  Basically, 1) the debt is manageable now, 2) they've sold off parts of the business at non-fire sale prices and 3) the parts that are left like Bausch and Lomb and some of the skin care stuff looks like a steady profitable business that Joe Papa can turn around.

Is anyone adding to this on the big dip?

Combining two generic drugs into one branded so they can jack up the price but can't even get it approved. Same old Valeant.

Didnít realize that they are trying to market just a combo of generics. That is why pharmacokinetics are so important - the FDA wants to understand, how these drugs interact. Otherwise, Doctors could just prescribe the term generics together (which I suspect occurs already anyways). Looks like VRX R&D department didnít d their job well.

VRX was designed not to have a functioning R&D team and they spend less than 4% of sales on R&D. Shouldn't be surprised when they screw up.

Liberty

  • Lifetime Member
  • Hero Member
  • *****
  • Posts: 10434
  • twitter.com/libertyRPF
    • twitter.com/libertyRPF
"Most haystacks don't even have a needle." |  I'm on Twitter  | Interesting podcast on aging research